Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin

X
Trial Profile

MAGELLAN - Multicenter, rAndomized, Parallel Group Efficacy and Safety for the Prevention of VTE in Hospitalized Medically iLL Patients Comparing rivaroxabAN With Enoxaparin

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 13 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rivaroxaban (Primary) ; Enoxaparin sodium
  • Indications Deep vein thrombosis; Pulmonary embolism; Stroke; Venous thromboembolism
  • Focus Registrational; Therapeutic Use
  • Acronyms MAGELLAN
  • Sponsors Bayer; Bayer HealthCare; Bayer Yakuhin; Janssen Research & Development
  • Most Recent Events

    • 07 Apr 2022 Results of a pooled analysis (MAGELLAN and MARINER trials data) assessed that the patients with major bleeding but not those with non-major clinically relevant bleeding, would be at an increased risk of all-cause mortality published in the Circulation
    • 23 Jan 2020 Results from MARINER and MAGELLAN trials published in the Thrombosis and Haemostasis.
    • 18 Nov 2019 Results (N= 16,496), post hoc analysis of the data pooled from two trials (MAGELLAN and MARINER Trials) assessing the efficacy of the extended thromboprophylaxis post to hospital discharge presented at the American Heart Association Scientific Sessions 2019
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top